TrialScientific reports2021

Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread.

Hung-Chih Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.